Trial Profile

A Single Pivotal Study of DMX-101 in Patients with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 09 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jul 2020 According to a Dermelix Biotherapeutics media release, the company anticipates to start this study in the second half of 2021.
25 Apr 2019 New trial record
02 Apr 2019 According to a Dermelix Biotherapeutics media release, Dermelix Biotherapeutics announced its partnership with EspeRare for DMX-101, a novel in utero protein replacement therapy for the rare pediatric disease X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com